Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients …
PJ Hesketh, M Aapro, JC Street, AD Carides - Supportive Care in Cancer, 2010 - Springer
Goals of work Certain patient and treatment characteristics are predictive of chemotherapy-
induced nausea and vomiting (CINV). Objectives of this analysis were:(1) confirm the …
induced nausea and vomiting (CINV). Objectives of this analysis were:(1) confirm the …
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea …
PJ Hesketh, SM Grunberg, J Herrstedt, R de Wit… - Supportive Care in …, 2006 - Springer
Goals of work Prevention of chemotherapy-induced nausea and vomiting (CINV) with
standard antiemetics has been more difficult to achieve in female patients. Data from two …
standard antiemetics has been more difficult to achieve in female patients. Data from two …
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor …
BL Rapoport, K Jordan, JA Boice, A Taylor… - Supportive Care in …, 2010 - Springer
Purpose Aprepitant was shown previously to be effective for prevention of chemotherapy-
induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in …
induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy (MEC) in …
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo …
PJ Hesketh, SM Grunberg, RJ Gralla… - Journal of clinical …, 2003 - ascopubs.org
Purpose: In early clinical trials with patients receiving highly emetogenic chemotherapy, the
neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic …
neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic …
Addition of the Oral NK1 Antagonist Aprepitant to Standard Antiemetics Provides Protection Against Nausea and Vomiting During Multiple Cycles of Cisplatin-Based …
R De Wit, J Herrstedt, B Rapoport… - Journal of clinical …, 2003 - ascopubs.org
Purpose: This analysis evaluated whether the antiemetic efficacy of the NK1 receptor
antagonist aprepitant (EMEND™, Merck, Whitehouse Station, NJ) plus standard antiemetics …
antagonist aprepitant (EMEND™, Merck, Whitehouse Station, NJ) plus standard antiemetics …
Cost‐effectiveness of aprepitant for the prevention of chemotherapy‐induced nausea and vomiting associated with highly emetogenic chemotherapy
S Moore, J Tumeh, S Wojtanowski, C Flowers - Value in health, 2007 - Wiley Online Library
Objective: Chemotherapy‐induced nausea and vomiting (CINV) is a significant problem for
cancer patients. Aprepitant, a novel NK‐1 receptor antagonist, is approved for use with 5 …
cancer patients. Aprepitant, a novel NK‐1 receptor antagonist, is approved for use with 5 …
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy‐induced nausea and vomiting
SP Chawla, SM Grunberg, RJ Gralla… - … Journal of the …, 2003 - Wiley Online Library
BACKGROUND The neurokinin‐1 antagonist aprepitant (EMEND™; Merck Research
Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea …
Laboratories, West Point, PA) has been shown to reduce chemotherapy‐induced nausea …
Why do we need another antiemetic? Just ask.
MG Kris - Journal of clinical oncology: official journal of the …, 2003 - europepmc.org
This is a comment on" The oral neurokinin-1 antagonist aprepitant for the prevention of
chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind …
chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind …
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study …
S Grunberg, D Chua, A Maru, J Dinis… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an
ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced …
ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced …
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting: Results …
S Poli‐Bigelli, J Rodrigues‐Pereira, AD Carides… - Cancer, 2003 - Wiley Online Library
BACKGROUND Aprepitant is a novel neurokinin 1 (NK1) antagonist that has been shown to
improve control of chemotherapy‐induced nausea and vomiting (CINV) when added to a …
improve control of chemotherapy‐induced nausea and vomiting (CINV) when added to a …